MyMD Pharmaceuticals’ Lead Compound MYMD-1 Shows Commonality in Comparative Study with FDA-Approved Anti-Inflammatory and Anti-Autoimmune Drugs Used for Arthritis, Colitis and Dermatitis
July 27 2021 - 9:15AM
Business Wire
- Study shows mechanisms of MYMD-1 deliver same outcomes as the
market-leading drugs for JAK inhibition in blocking the genes that
trigger inflammation and autoimmunity
- Global market for JAK inhibitors projected to exceed $300
billion by 2026 according to a report by 360 Market Updates
MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the
Company”), a clinical stage pharmaceutical company committed to
extending healthy lifespan by focusing on developing two
therapeutic platforms, today announced data from a comparative
study conducted by Eurofins Discovery showing commonality between
its lead clinical compound MYMD-1 and three FDA-approved JAK
inhibitor drugs for the treatment of autoimmune and inflammatory
diseases.
Janus Kinases (JAKs) are enzymes found in cells in the immune
system that are critical for the cell signaling process. JAK
inhibitors block the inflammatory signaling pathways, inhibiting
the genes that trigger autoimmune processes.
“This new comparative data adds to the growing body of evidence
demonstrating MYMD-1’s efficacy in preventing and treating a range
of inflammatory and autoimmune diseases,” said Chris Chapman, M.D.,
President, Director and Chief Medical Officer of MyMD. “JAK
inhibitor drugs alone represent an $11 billion global market today,
growing to a $300 billion-plus global market by the end of 2026,
according to data from 360 Market Updates. That is only a fraction
of the total market for anti-inflammatory drugs. With only a few
FDA-approved JAK inhibitors on the market today, there is ample
opportunity for new related products to capture a significant share
of this massive addressable market.”
The FDA has issued Boxed Warnings for one of the marketed JAK
inhibitor drugs used in the comparative study. The public was
notified of serious side effects including an increased risk of
blood clots in the lungs and death in rheumatoid arthritis patients
taking a standard dose of the product.
Dr. Chapman noted, “The FDA safety alert was specific to the
mechanisms of that particular drug alone, not to the safety profile
of JAK inhibition as a treatment. There are many successful and
effective treatments for autoimmune diseases on the market, and JAK
inhibition is only one therapeutic strategy. As an inhibitor of two
of the key drivers of chronic inflammation – JAKs and tumor
necrosis factor-alpha (TNF-α) – we are confident that MYMD-1 will
become a high value next generation immunometabolic regulator for
autoimmune and age-related diseases.”
In addition to JAK inhibition, MYMD-1 has shown efficacy as a
selective inhibitor of TNF-α, a driver of chronic inflammation.
MYMD-1 has also been shown to be effective in traversing the
blood-brain barrier, a differentiator that can increase the drug’s
benefit to patients.
About MyMD Pharmaceuticals, Inc.
MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) is a clinical stage
pharmaceutical company committed to extending healthy lifespan by
focusing on developing two therapeutic platforms. MYMD-1 is a drug
platform based on a clinical stage small molecule that regulates
the immunometabolic system to control TNF-α and other
pro-inflammatory cytokines. MYMD-1 is being developed to treat
autoimmune diseases, including those currently treated with
non-selective TNF-α blocking drugs, and aging and longevity. The
Company’s second drug platform, Supera-CBD, is based on a novel
(patent pending) synthetic derivative of cannabidiol (CBD) that
targets numerous key receptors including CB2 and opioid receptors
and inhibits monoamine oxidase. Supera-CBD is being developed to
address the rapidly growing CBD market, that includes FDA approved
drugs and CBD products not currently regulated as a drug. For more
information, visit www.mymd.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release may contain forward-looking statements. These
forward-looking statements involve known and unknown risks,
uncertainties and other factors which may cause actual results,
performance or achievements to be materially different from any
expected future results, performance, or achievements.
Forward-looking statements speak only as of the date they are made
and none of MyMD nor its affiliates assume any duty to update
forward-looking statements. Words such as "anticipate," "believe,"
"could," "estimate," "expect," "may," "plan," "will," "would'' and
other similar expressions are intended to identify these
forward-looking statements. Important factors that could cause
actual results to differ materially from those indicated by such
forward-looking statements include, without limitation: the timing
of, and MyMD’s ability to, obtain and maintain regulatory approvals
for clinical trials of MyMD’s pharmaceutical candidates; the timing
and results of MyMD’s planned clinical trials for its
pharmaceutical candidates; the amount of funds MyMD requires for
its pharmaceutical candidates; increased levels of competition;
changes in political, economic or regulatory conditions generally
and in the markets in which MyMD operates; MyMD’s ability to retain
and attract senior management and other key employees; MyMD’s
ability to quickly and effectively respond to new technological
developments; MyMD’s ability to protect its trade secrets or other
proprietary rights, operate without infringing upon the proprietary
rights of others and prevent others from infringing on MyMD’s
proprietary rights; and the impact of the ongoing COVID-19 pandemic
on MyMD’s results of operations, business plan and the global
economy. A discussion of these and other factors with respect to
MyMD is set forth in the Quarterly Report on Form 10-Q for the
quarterly period ended March 31, 2021, filed by MyMD on May 18,
2021. Forward-looking statements speak only as of the date they are
made and MyMD disclaims any intention or obligation to revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210727005570/en/
Investor Contact: Robert Schatz (646) 421-9523
rschatz@mymd.com www.mymd.com
Media Contact: Will Johnson 201-465-8019
MYMD@antennagroup.com www.antennagroup.com
MyMD Pharmaceuticals (NASDAQ:MYMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
MyMD Pharmaceuticals (NASDAQ:MYMD)
Historical Stock Chart
From Sep 2023 to Sep 2024